Cagrilintide

Laboratory Handling Directions

• Store at controlled room temperature (15–25°C / 59–77°F)
• Protect from light and moisture during storage
• Use aseptic technique when handling compound
• Reconstitute with bacteriostatic water as appropriate
• Once reconstituted, refrigerate at 2–8°C (36–46°F)
• Document all handling procedures per laboratory protocols
  

Mechanism of Action

Cagrilintide research peptide primarily acts as a long-acting analog mimicking endogenous amylin, binding to amylin receptors (AMY1R, AMY2R, AMY3R) and calcitonin receptors (CTR) in the brain and periphery to enhance satiety via hypothalamic and hedonic pathways. Furthermore, it slows gastric emptying, suppresses postprandial glucagon release, and reduces food intake without stimulating insulin in a glucose-dependent manner, while structural modifications like N-terminal lipidation extend its half-life through albumin binding and proline substitutions prevent fibril formation. Additionally, laboratory models reveal distinct conformational dynamics at calcitonin-family receptors compared to native amylin, contributing to sustained signaling, reduced meal frequency, and improved energy homeostasis. These actions, observed in rodent knockout studies and receptor binding assays, support observed reductions in body weight and fat mass while preserving lean tissue, with recent research emphasizing its reassuring profile for balanced amylin pathway activation and complementary effects in metabolic models.

Research Applications

• Amylin and calcitonin receptor activation investigations

• Satiety signaling and appetite regulation mechanism analysis

• Gastric emptying delay and food intake studies

• Glucagon suppression and postprandial glucose evaluations

• Weight management and energy balance pathway research

• Dual receptor dynamics and anti-obesity effects examinations in metabolic models

Scientific References

• Cooper GJS et al. Proc Natl Acad Sci USA. 1987;84(23):8628-8632
• Hay DL et al. Pharmacol Rev. 2015;67(3):564-600
• Mack CM et al. J Pharmacol Exp Ther. 2010;334(2):409-422
• Rushing PA et al. Endocrinology. 2000;141(2):850-857